In the last month, funds linked to central enterprises have ramped up their investment activities in the hard tech sector. Notably, Embodied AI firm Xingdong Era has clinched a RMB 1 billion lead investment from Chengtong Fund. Meanwhile, physical AI company Tsingyan Precision has garnered strategic investment from Sinomach Industrial Fund, and Shanxi CETC has secured leading investment from China Reform Fund. In strategic emerging fields like embodied AI, semiconductor equipment, and quantum computing, the 'patient capital' provided by central enterprises is swiftly expanding its footprint—a move that can be aptly described as 'intensifying deployment' in this context.

Presently, capital from central enterprises is increasingly directed towards the earlier stages of technological innovation, demonstrating a willingness to lead the charge in sectors characterized by long development cycles. By harnessing 'patient capital,' these enterprises are not only facilitating the shift of future industries from the research lab to full-scale industrialization but also utilizing capital as a vital connector to maintain autonomous control over industrial and supply chains.